515 related articles for article (PubMed ID: 9786514)
1. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
2. Radioiodinated substance P, neurokinin A, and eledoisin bind predominantly in NK1 receptors in guinea pig lung.
Geraghty DP; Mussap CJ; Burcher E
Mol Pharmacol; 1992 Jan; 41(1):147-53. PubMed ID: 1370705
[TBL] [Abstract][Full Text] [Related]
3. Further evidence for the presence of "septide-sensitive" tachykinin binding sites in tissues possessing solely NK(1) tachykinin receptors.
Torrens Y; Beaujouan JC; Saffroy M; Glowinski J
Biochem Biophys Res Commun; 2000 Apr; 270(2):668-72. PubMed ID: 10753681
[TBL] [Abstract][Full Text] [Related]
4. Characterization of [3H]substance P binding sites in human skin.
Bianchi B; Matucci R; Danesi A; Rossi R; Ipponi P; Giannotti B; Johansson O; Cappugi P
J Eur Acad Dermatol Venereol; 1999 Jan; 12(1):6-10. PubMed ID: 10188142
[TBL] [Abstract][Full Text] [Related]
5. Identification in the NK1 tachykinin receptor of a domain involved in recognition of neurokinin A and septide but not of substance P.
Wijkhuisen A; Sagot MA; Frobert Y; Créminon C; Grassi J; Boquet D; Couraud JY
FEBS Lett; 1999 Mar; 447(2-3):155-9. PubMed ID: 10214937
[TBL] [Abstract][Full Text] [Related]
6. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
7. Septide: an agonist for the NK1 receptor acting at a site distinct from substance P.
Pradier L; Ménager J; Le Guern J; Bock MD; Heuillet E; Fardin V; Garret C; Doble A; Mayaux JF
Mol Pharmacol; 1994 Feb; 45(2):287-93. PubMed ID: 7509440
[TBL] [Abstract][Full Text] [Related]
8. Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis.
Hastrup H; Schwartz TW
FEBS Lett; 1996 Dec; 399(3):264-6. PubMed ID: 8985159
[TBL] [Abstract][Full Text] [Related]
9. Kinetic binding and activation profiles of endogenous tachykinins targeting the NK1 receptor.
Nederpelt I; Bleeker D; Tuijt B; IJzerman AP; Heitman LH
Biochem Pharmacol; 2016 Oct; 118():88-95. PubMed ID: 27501920
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
11. Gly166 in the NK1 receptor regulates tachykinin selectivity and receptor conformation.
Ciucci A; Palma C; Riitano D; Manzini S; Werge TM
FEBS Lett; 1997 Oct; 416(3):335-8. PubMed ID: 9373180
[TBL] [Abstract][Full Text] [Related]
12. Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells.
Cooke HJ; Fox P; Alferes L; Fox CC; Wolfe SA
Can J Physiol Pharmacol; 1998 Feb; 76(2):188-93. PubMed ID: 9635159
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.
Cascieri MA; Ber E; Fong TM; Sadowski S; Bansal A; Swain C; Seward E; Frances B; Burns D; Strader CD
Mol Pharmacol; 1992 Sep; 42(3):458-63. PubMed ID: 1383685
[TBL] [Abstract][Full Text] [Related]
14. Residue 78 in the second transmembrane domain of the neurokinin-1 receptor is important in coupling high affinity agonist binding to multiple second messenger responses.
Brodbeck RM; Sachais BS; Krause JE
Mol Pharmacol; 1995 May; 47(5):1065-71. PubMed ID: 7538194
[TBL] [Abstract][Full Text] [Related]
15. Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors.
Cascieri MA; Huang RR; Fong TM; Cheung AH; Sadowski S; Ber E; Strader CD
Mol Pharmacol; 1992 Jun; 41(6):1096-9. PubMed ID: 1377326
[TBL] [Abstract][Full Text] [Related]
16. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor-1.
Nakamura M; Ofuji K; Chikama T; Nishida T
Br J Pharmacol; 1997 Feb; 120(4):547-52. PubMed ID: 9051288
[TBL] [Abstract][Full Text] [Related]
17. High-affinity substance P binding sites of neurokinin-1 receptor type autoradiographically associated with vascular sinuses and high endothelial venules of human lymphoid tissues.
Tang SC; Fend F; Müller L; Braunsteiner H; Wiedermann CJ
Lab Invest; 1993 Jul; 69(1):86-93. PubMed ID: 7687312
[TBL] [Abstract][Full Text] [Related]
18. Substance P(6-11) and natural tachykinins interact with septide-sensitive tachykinin receptors coupled to a phospholipase C in the rat urinary bladder.
Torrens Y; Saffroy M; Glowinski J; Beaujouan JC
Neuropeptides; 1997 Jun; 31(3):243-51. PubMed ID: 9243521
[TBL] [Abstract][Full Text] [Related]
19. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
[TBL] [Abstract][Full Text] [Related]
20. High affinity binding sites for [3H]substance P in urinary bladders of cats with interstitial cystitis.
Buffington CA; Wolfe SA
J Urol; 1998 Aug; 160(2):605-11. PubMed ID: 9679937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
